GEN News Highlights: Aug 11, 2011

GE Healthcare to Provide Customers with On-Site Service and Support for AB Sciex Mass Spec Systems

(Page 1 of 1)

    GE Healthcare has decided to offer its Smart Asset Management Services (SAMS) customers throughout North America the option for full on-site service and maintenance support of AB Sciex mass spectrometry systems.

    Under their collaboration agreement, AB Sciex will supplement with its own service and support staffers the on-site work of GE Healthcare service engineers “when needed,” according to GE Healthcare. The company says that its arrangement offered the advantages of enhanced efficiency and a single point of contact for service support of U.S. and Canadian SAMS customers.

    Last week AB Sciex announced that Tetsuya Terasaki and his research team at Japan’s Tohoku University, which focuses on studying the the blood-brain barrier, credited the company’s TripleTOF 5600 System and Eksigent chip-based system with allowing them to identify and quantify a much wider range than previously possible for drug transporter proteins, important functional proteins such as cytochrome P450 and UGT proteins in complex matrices, and enzymes that activate or inactivate drugs in the body.


Related content

GEN News Highlights

Insight & Intelligence™

GEN Articles

Application Notes

Webinars

Video Channel

New Products

Best of the Web

Subscription center

GEN MAGAZINE

Genetic Engineering & Biotechnology News (GEN) has retained its position as the most widely read biotechnology publication around the globe since its launch in 1981. Published 21 times a year and with additional exclusive editorial content online, GEN's unique news and technology focus includes the entire bioproduct life cycle from early-stage R&D, to applied research including omics, biomarkers, as well as diagnostics, to bioprocessing and commercialization.

Subscribe

e-NEWSLETTERS

Add GEN to your Inbox! Subscribe today to our complimentary e-newsletters and stay abreast of the latest biotech news and trends. Click the magnifying glass icon next to a newsletter title to view a sample.

 

All fields are required

Email
  Confirm Email
  First Name
  Last Name
  Organization
  E-Alert Format
 
 
  Sign Up

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

GENpoll

FDA Performance

How much progress do you think FDA has made in reviewing drugs and bringing them to market faster?

Suggest a Poll